Abstract Number: 1300 • 2018 ACR/ARHP Annual Meeting
The Relationship between Metabolic Syndrome Severity and the Risk of Mortality in Gout Patients: A Population Based Study
Background/Purpose: The metabolic syndrome (MS) is common among gout patients. The metabolic syndrome is diagnosed when a patient has at least 3 of the following…Abstract Number: 1301 • 2018 ACR/ARHP Annual Meeting
Organic Anion Transport Inhibitors Suppress Chondrocyte Pyrophosphate Production
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease results from articular calcium pyrophosphate deposition leading to arthritis. We currently lack specific and effective therapies for this commonly…Abstract Number: 1302 • 2018 ACR/ARHP Annual Meeting
Opioid Analgesic Use in Acute Gout Patients Discharged from the Hospital
Background/Purpose: The Health and Human Services has declared the opioid epidemic as a public health emergency. It has been demonstrated that even short exposures to…Abstract Number: 1303 • 2018 ACR/ARHP Annual Meeting
Rituximab Versus Mycophenolate Mofetil in Interstitial Lung Disease Secondary to Connective Tissue Disease
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in connective tissue diseases (CTD). CTD-related ILD (CTD-ILD) has typically been treated…Abstract Number: 1304 • 2018 ACR/ARHP Annual Meeting
Rituximab in Connective Tissue Disease – Associated Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbi-mortality in patients (pts) with CTD. Small studies have recently demonstrated a promising role for…Abstract Number: 1305 • 2018 ACR/ARHP Annual Meeting
Risk of Progression of Interstitial Lung Disease with Autoimmune Features to a Systemic Autoimmune Rheumatic Disease
Background/Purpose: Approximately 15-25% of patients diagnosed with idiopathic interstitial lung disease (ILD) have some features of autoimmunity, yet do not meet classification criteria for a…Abstract Number: 1306 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Treatment Patterns in Patients with Interstitial Pneumonia with Autoimmune Features (IPAF)
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) has recently been defined to describe patients with interstitial lung disease (ILD) with certain clinical, serologic, and/or morphologic…Abstract Number: 1307 • 2018 ACR/ARHP Annual Meeting
Autoantibodies in Idiopathic Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features – a Prospective Study
Background/Purpose: The detection of autoantibodies plays a vital role in the diagnosis of occult connective tissue disease (CTD) in patients with interstitial lung disease (ILD),…Abstract Number: 1308 • 2018 ACR/ARHP Annual Meeting
Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD):a Single Center Study of 47 Patients
Background/Purpose: Interstitial lung disease (ILD) is a fatal complication of connective tissue diseases (CTDs). Despite numerous advances in immunosuppressive agents, data on effective treatment for…Abstract Number: 1309 • 2018 ACR/ARHP Annual Meeting
Interstitial Pneumonia with Autoimmune Features: Is It Frequent?
Background/Purpose: A particular subset of interstitial pneumonia, associated to one or more clinical and serological features, suggesting a possible underlying autoimmune disorder, has been described…Abstract Number: 1310 • 2018 ACR/ARHP Annual Meeting
Diagnostic Utility of Myositis Antibodies in Patients with Interstitial Lung Disease and Suspected Underlying Connective Tissue Disease
Background/Purpose: Interstitial Lung Disease (ILD) is a common manifestation of Connective Tissue Diseases (CTD), mainly Systemic sclerosis (SSc), Rheumatoid Arthritis and Idiopathic Inflammatory Myositis (IIM)…Abstract Number: 1311 • 2018 ACR/ARHP Annual Meeting
A Multidisciplinary Cohort of Patients with Interstitial Pneumonia with Autoimmune Features
Background/Purpose: Interstitial Lung Disease (ILD) remains a significant diagnostic and therapeutic challenge, especially for patients who do not meet criteria for a connective tissue disease…Abstract Number: 1312 • 2018 ACR/ARHP Annual Meeting
Interstitial Pneumonia with Autoimmune Features (IPAF)-Nsip: Hurdles to Reclassification of Overlapping Ilds
Background/Purpose: Interstitial lung disease (ILD) may occur in the presence of autoimmune elements without meeting criteria for a distinctive Connective Tissue Disease. The European Respiratory…Abstract Number: 1313 • 2018 ACR/ARHP Annual Meeting
Clinical Features and Timing of Studies in Interstitial Lung Disease with Autoimmune Disease Features: Do Autoantibody Panels Improve Diagnostic Yields and/or Increase Costs?
Background/Purpose: The entity of interstitial lung disease with autoimmune disease features (ILD-AF) is increasingly gaining traction as condition that is best co-managed by pulmonologists and…Abstract Number: 1314 • 2018 ACR/ARHP Annual Meeting
Autoantibodies and Clinical Outcomes in Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases
Background/Purpose: Pulmonary arterial hypertension (PAH) associated with SSc (SSc-PAH) has a substantially worse prognosis as compared to other connective tissue diseases (CTD)-PAH. Although SSc-PAH are…
ACR Meeting Abstracts